Nitches Inc. (NICH)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2007
Period Ending	May 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2007
Revenue	0.01	0	0	-	-	84.94
Revenue Growth (YoY)	31.55%	494.93%	-	-	-	54.92%
Cost of Revenue	0.01	0.02	0.01	-	-	64.59
Gross Profit	-0	-0.02	-0	-	-	20.36
Selling, General & Admin	0.09	0.42	0.83	14.17	0.01	20.62
Operating Expenses	0.09	0.43	0.83	14.17	0.01	20.62
Operating Income	-0.09	-0.44	-0.84	-14.17	-0.01	-0.26
Interest Expense	-1.87	-0.61	-0	-0.01	-	-1.04
Other Non Operating Income (Expenses)	-0.04	0.22	0.01	-5	-	-
EBT Excluding Unusual Items	-2	-0.83	-0.83	-19.18	-0.01	-1.3
Pretax Income	-2	-0.83	-0.83	-19.18	-0.01	-1.3
Income Tax Expense	-	-	-	-	-	-0.36
Net Income	-2	-0.83	-0.83	-19.18	-0.01	-0.94
Net Income to Common	-2	-0.83	-0.83	-19.18	-0.01	-0.94
Free Cash Flow	-0.05	-0.46	-0.49	-0.13	-	-1.65
Gross Margin	-0.73%	-	-	-	-	23.96%
Operating Margin	-1807.16%	-10492.42%	-118081.97%	-	-	-0.31%
Profit Margin	-38352.63%	-19579.02%	-117483.66%	-	-	-1.10%
Free Cash Flow Margin	-1021.24%	-10958.83%	-69204.37%	-	-	-1.94%
EBITDA	-0.09	-0.44	-0.84	-	-	0.1
EBITDA Margin	-	-	-	-	-	0.11%
D&A For EBITDA	0.01	0.01	0	-	-	0.36
EBIT	-0.09	-0.44	-0.84	-14.17	-0.01	-0.26
EBIT Margin	-	-	-	-	-	-0.31%

Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.